HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Personalizing IBS Treatment With Digital Therapy

Executive Summary

Sanofi Consumer Healthcare has teamed up with digital health player Cara Care to offer an innovative treatment for IBS which goes beyond the pill and helps sufferers access personalized support for their illness.

You may also be interested in...



UK Marketing: Sanofi Launches Buscomint, New Releases From Salonpas and Nailner

The latest OTC launches in the UK, including Buscomint from Sanofi, Salonpas Gel-Patch from Hisamitsu and Nailner Active Cover from Karo.

Sanofi Tapping AI To Help Consumers Manage IBS

Sanofi is utilizing AI technology to help UK consumers to better manage their IBS and digestive symptoms. 

What A Relief! Three German IBS Launches From Sanofi, Dr Kade, Dr Loges

Sanofi on trend with plant-based, app-supported Buscopan line extension, Dr Kade offers all-in-one gastrointestinal product and Dr Loges appeals to children with blueberry flavored supplement. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel